AI-powered medical image analysis specialist Thirona has received funding from Belgian investment fund HERAN Partners and the Netherlands-based Borski Fund.
Thirona develops artificial intelligence solutions for lung and retinal image analysis.
It focuses on common diseases such as Asthma, COPD, Age-related Macular Degeneration and Diabetic Retinopathy, as well as rare and complex conditions, including Cystic Fibrosis and Idiopathic Pulmonary Fibrosis.
Eva van Rikxoort, founder and CEO of Thirona, said: “We believe that science should be used for the benefit of all people. Our vision is to speed up scientific progress in healthcare by bringing together the best of science and technology. This will enable breakthroughs in treatment development and clinical care.
Thirona bosses say it focuses on translating AI-based technology into value-adding solutions and services for the user.
With its flagship product, LungQ™, the company has worked to advance treatment development in clinical trials and support pulmonary clinical care across the globe.
The company is now looking to expand its operations and scale up its development efforts.
Guido Geerts. co-CEO of Thirona, said: “As a company, we have always placed a high emphasis on research and development which has enabled us to establish strong academic, clinical and industrial partnerships.
“Now, we find ourselves at a tipping point in our journey, expediting our international expansion and development goals. We are pleased to have found the right partners in HERAN Partners and Borski Fund to help accelerate our growth trajectory.”
Katleen Vandersmissen, managing partner at HERAN Partners said: “We are committed to supporting Thirona’s growth plans and providing them with capital, network, and expertise in global commercialisation.
Bertrand van Leersum, investment director at Borski Fund said: “We are pleased to add Thirona to our portfolio as the third medical company.
“We look very much forward to supporting Eva and the management team in their personal and organisational growth.”
